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Abstract
Background:  The use of mouse models for the study of thrombotic disorders has gained
increasing importance. Methods for measurement of coagulation activation in mice are, however,
scarce. The primary aim of this study was to develop a specific mouse thrombin-antithrombin
(TAT) ELISA for measurement of coagulation activation and to compare it with two commercially
available assays for human TAT complexes. In addition, we aimed to improve methods for mouse
plasma anticoagulation and preparation.
Methods and results: First, for the measurement of TAT-complexes in plasma a mouse specific
TAT-ELISA was developed using rabbit polyclonal antibodies raised against mouse thrombin and
rat antithrombin, respectively. This ELISA detected an increase in TAT levels in a mouse model of
endotoxemia. Two commercial human TAT ELISAs appeared to be less specific for mouse
thrombin-rat antithrombin complexes.
Second, to prevent clotting of mouse blood sodium citrate was either mixed with blood during
collection in a syringe or was injected intravenously immediately prior to blood collection.
Intravenous sodium citrate completely inhibited blood coagulation resulting in plasma with
consistently low TAT levels. Sodium citrate mixed with blood during collection resulted in
increased TAT levels in 4 out of 16 plasma samples. Third, heparinase was added to plasma samples
after in vivo injection of different heparin doses to test its neutralizing effect. Heparinase
neutralized up to a 20 U of heparin/mouse and resulted in accurate APTT and factor VIII
determinations.
Conclusion: These procedures and reagents for plasma preparation and coagulation testing will
improve studies on thrombotic disorders in mice.
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Background
Since the identification of genes encoding mouse clotting
proteins and the creation of a growing number of trans-
genic mice, the use of mouse models for the study of
thrombotic disorders has gained increasing interest [1].
While methodology for determining fibrin deposition in
tissues [2] and quantification of thrombus formation
[2,3] is readily available, optimal utilization of blood
samples from mice remains a poorly explored area.
The availability of proper laboratory assays is essential in
order to study coagulation activation in mice, comparably
to humans. There is, however, a striking lack of analytical
methods to test coagulation activation specifically in
mice. For human studies, several commercial assays are
available, including assays for thrombin-antithrombin
(TAT) complexes to test in vivo coagulation activation
[4,5]. When these assays, based on antibody detection of
human protein epitopes, are applied on mouse plasma, it
is likely that difficulties can arise depending on the degree
of interspecies cross-reactivity, sensitivity, and specificity.
A practical issue of importance is that, traditionally,
research on blood coagulation depends on determination
of the activity of coagulation factors in a plasma sample.
For this purpose specific anticoagulants, including
sodium citrate or cocktails of substances need to be added
to blood samples, in order to prevent ex vivo clotting.
While even in humans the collection of proper plasma
samples is not without practical problems, the collection
of plasma from mice is a major technical challenge. As far
as we know, there are no published procedures for antico-
agulation that specifically address plasma sampling in
mouse.
The use of mouse models enables investigations into the
mechanism of coagulation activation in plasma as well as
its consequences, i.e. fibrin deposition and pathological
changes in organs, simultaneously. However, for proper
tissue collection procedures such as heparinization are fre-
quently required, which impairs most conventional tests
of plasmatic coagulation. Human studies showed that
addition of heparinase to plasma samples neutralized up
to 2 U/ml heparin resulting in accurate factor VIII deter-
minations [6]. In order to minimize interference of
heparin we tested the effect of heparinase added to mouse
plasma samples following in vivo heparinization.
In this study we developed a new mouse specific TAT
ELISA and validated this method using a mouse model of
endotoxemia, characterized by enhanced coagulation
activation. Furthermore, we compared this new ELISA
with two commercially available human immunoassays
for measuring thrombin-antithrombin complexes in
mouse plasma samples collected by different blood col-
lection procedures.
Methods
Animals
All studies were performed in male mice of the C57Bl/6
strain (University of Maastricht or Academic Medical
Center, Amsterdam), which were 8 weeks old and weigh-
ing approximately 20 grams at the start of the experi-
ments. The animals were housed in normal cages in an
environment with a 12 hour light-dark cycle, controlled
temperature (20 ± 2°C) and humidity (50 ± 10%). Ani-
mals had free access to water and diets (Hope Farms,
Woerden, The Netherlands). Endotoxemia studies were
performed by i.p. injection of 2 mg lipopolysaccharide
(LPS, E. coli, Sigma, St.Louis, MO) per kg. The Experimen-
tal Animal Ethics Committee of the University Maastricht
and of the Academic Medical Center, Amsterdam
approved all experimental protocols.
Chemicals
All reagents were of analytical grade or better and were
from commercial suppliers.
Development of TAT-ELISA
Rabbit immunization
Mouse thrombin (Sigma, St.Louis, MO, USA) and rat anti-
thrombin (AT) (Sigma) were dissolved in PBS (150
mmol/L NaCl, 10 mmol/L sodium phosphate, pH 7.4), to
a concentration of 200 and 140 µg/ml, respectively. Fif-
teen-week old New Zealand White rabbits, weighing
approximately 3 kilograms were obtained from Harlan
(Cambridge, UK). Immediately before immunization
with thrombin and AT, pre-immune sera were collected.
Thereafter, each rabbit was immunized with a mixture of
500 µl Freund's Complete Adjuvant (Difco, Detroit, MI,
USA) and 500 µl protein solution. For each protein, two
rabbits were injected twice s.c. on the back and twice i.m.
in the hind legs. The rabbits were boosted at nine and 15
weeks after the first immunization with thrombin and AT
in combination with Freund's Incomplete Adjuvant
(Difco). During the first three months test samples of
approximately five ml blood were obtained regularly and
thereafter samples of approximately 50 ml were obtained
monthly from each rabbit.
Reactivity of rabbit antisera for TAT ELISA
MaxiSorp plates (Nunc A/S, Roskilde, Denmark) were
coated overnight at 4°C with 100 µl thrombin or AT in a
concentration of 5 µg/ml diluted in coating buffer (70
mM Na2CO3, 30 mM NaHCO3, pH 9). Subsequently, the
plates were washed three times with PBS, 0.05 %(v/v)
Tween (PBS/Tween) and incubated with 100 µl rabbit sera
diluted in PBS, 0.05 %(v/v) Tween, 1 %(v/v) FCS (PBS/
Tween/FCS). The plates were incubated for 1 hour atThrombosis Journal 2005, 3:12 http://www.thrombosisjournal.com/content/3/1/12
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room temperature and washed three times with PBS/
Tween. Thereafter, the plates were incubated for 1 hour
with 100 µl horseradish peroxidase (HRP)-conjugated
swine anti-rabbit antibodies (DAKO A/S, Glostrup, Den-
mark) diluted 250-times in PBS/Tween/FCS. The plates
were washed three times with PBS/Tween and developed
with o-phenylenediamine (OPD, Sigma) for 30 minutes.
The reaction was stopped with 100 µl 1 M H2SO4 and the
optical density (OD) was determined at 490 and 650 nm.
Calculations were performed using the SOFTmax software
from Molecular Devices Corporation (Sunnyvale, CA,
USA).
Purification of rabbit antibodies and conjugation to digoxigenin (DIG) 
for TAT ELISA
Three ml rabbit serum, 1/10 diluted with 200 mM sodium
phosphate pH 7, was applied on a HiTrap Protein A col-
umn (Pharmacia LKB, Uppsala, Sweden). Before applica-
tion of the sample the column was equilibrated with five
column volumes 20 mM sodium phosphate, pH 7. After
application of the sample the column was washed with 5
volumes 20 mM sodium phosphate and the rabbit IgG
was eluted with 100 mM citric acid, pH 5. The pH of the
IgG-elution sample was adjusted with 1 M Tris-HCl to pH
7 and dialyzed overnight at 4°C against PBS. The concen-
tration of the purified IgG samples was adjusted to 1 mg/
ml. One ml sample was incubated in a glass tube at RT
under continuously shaking with 47 µl DIG-NHS
uitleggen? ester (5 mg/ml, Roche Diagnostics). The sam-
ples were dialyzed overnight against PBS and frozen in
aliquots at -20°C.
In vitro generation of TAT-complexes
TAT-complexes were generated in vitro according to the
method from Boisclair et al. (7). Briefly, 50 µg mouse
thrombin and 140 µg rat antithrombin were dissolved in
330 µl TAT-buffer (50 mM Tris, 175 mM NaCl, 0.02%
sodium azide, 0.1% PEG-6000, 4% BSA, pH 7.9) and
incubated for 45 minutes at 37°C. The samples were aliq-
uoted in 20 µl portions and frozen at -20°C.
Western blot analysis
Western blot samples were prepared as follows: 5 µl 5x
sample buffer (250 mM Tris-HCl pH 6.8, 10% SDS, 50%
Glycerol) was added to 20 µl thrombin (50 µg/ml), 20 µl
AT (50 µg/ml) or 20 µl in vitro TAT-complexes. The sam-
ples were prepared without addition of β-mercaptoetha-
nol and were not denatured by heating because this
results in aggregation of the in vitro TAT complexes in the
PEG-6000 containing buffer. Plasma samples were pre-
pared by combining 20 µl plasma, 20 µl 5x sample buffer
and 60 µl H2O. Ten µl of each sample was separated on a
7.5% acrylamide gel and transferred by electroblotting to
a nitrocellulose filter (Schleicher and Schuell, Dassel, Ger-
many). After washing for 5 minutes with PBS/1%Tween
and blocking for 1 hour at RT in PBS/Tween/5% (v/v)
Milk the filters were incubated with 1/1000 diluted rabbit
serum in PBS/Tween. After three washes of 10 minutes
with PBS/Tween the blots were incubated for 1 hour at RT
with HRP-conjugated swine anti-rabbit IgG diluted 250-
fold in PBS/Tween. Finally, the blots were washed with
PBS/Tween and H2O and incubated with a chemolumi-
nescencent substrate (LumiLight, Roche Diagnostics,
Mannheim, Germany). The pre-stained low range SDS
PAGE markers (Bio-Rad Laboratories, Hercules, CA, USA)
were used as molecular weight marker.
Sandwich TAT-complex ELISA
TAT-levels in plasma were detected with the new mouse
TAT ELISA as follows: MaxiSorp plates were coated over-
night at 4°C with 100 µl purified anti-thrombin antibod-
ies in a concentration of 1 µg/ml in coating buffer.
Subsequently, the plates were washed three times with
PBS/Tween and incubated with 50 µl standard or 4-fold
diluted plasma samples in PBS/Tween/FCS for 1 hour on
a shaker at room temperature. The plates were washed
three times with PBS/Tween and incubated with 100 µl
purified DIG-conjugated anti-AT antibodies in a concen-
tration of 0.5 µg/ml for 1 hour at room temperature. The
plates were washed three times with PBS/Tween and incu-
bated for 1 hour at room temperature with 100 µl HRP-
conjugated sheep F(ab)2 anti-DIG fragments (Roche
Diagnostics) diluted in PBS/Tween. The plates were devel-
oped with OPD for 30 minutes and after termination of
the reaction with 1 M H2SO4 the OD was determined at
490 and 650 nm. A standard for the mouse TAT ELISA was
constructed with two-fold serial dilutions of mouse
thrombin – rat antithrombin complexes (Sigma) in PBS/
Tween/FCS buffer or mouse plasma.
Detection of TAT-complexes with three different ELISA's
The newly developed TAT-ELISA was compared with two
commercially available ELISAs according to the manufac-
turer's instructions: Enzygnost® TAT micro (DadeBehring
BV, Leusden, The Netherlands) and TAT ELISA (Enzyme
Research Laboratories (ERL), South Bend, IN, USA). For
this purpose, in vitro TAT complexes were measured as
standard and diluted in either buffer or normal mouse
pool plasma. In addition, TAT-levels measured in plasma
from control and LPS-treated (2 mg/kg i.p., 6 hours) mice,
were compared.
Plasma collection procedures
Anti-coagulation with sodium citrate
Two methods of anticoagulation with sodium citrate were
compared. In the first procedure, 900 µl blood was drawn
from the vena cava into a syringe containing 100 µl 3.2%
(w/v) sodium citrate. For the second approach 3.2% (w/
v) sodium citrate in a total volume of body weight (gr) /
13 × 100 µl was i.v. administrated in the vena cava 20–30Thrombosis Journal 2005, 3:12 http://www.thrombosisjournal.com/content/3/1/12
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seconds prior to blood drawing from the same vein into a
syringe. Blood samples were centrifuged for 15 minutes at
3000 rpm at RT, subsequently plasma was centrifuged for
5 minutes at 13 000 rpm to remove remaining cells and
platelets, and immediately frozen at -80°C.
Neutralizing heparin in plasma
Mice were anticoagulated by intravenous injection of 0, 4,
20 or 400 units heparin (Leo Pharmaceuticals, Weesp, The
Netherlands), diluted in approximately 200 µl water for
injection. After 5 minutes blood samples of approxi-
mately 700 µl were obtained by exsanguination via the
vena cava into a syringe containing 0.1 volume 3.2% (w/
v) sodium citrate. The plasma samples were centrifuged
for 10 minutes at 3000 rpm and immediately frozen at -
80°C until use. After thawing, a quarter of a heparinase
tablet (Dade Hepzyme, Dade Behring, Marburg, Ger-
many) was added to 150 µl of plasma sample in a plastic
tube, mixed gently and incubated at room temperature for
15 minutes. Then, activated partial thromboplastin time
(APTT) and factor VIII were measured with standard pro-
cedures with a Behring Coagulation System (BCS, Dade
Behring) using human reagents as provided by the manu-
facturer. For factor VIII measurements human FVIII defi-
cient plasma (Dade Behring) was used.
Statistical analysis
Data are presented as mean with SEM. Differences
between two groups were tested with students' t test. Dif-
ferences between three groups were tested by one way
ANOVA. P < 0.05 was set as threshold of statistical signif-
icance. All computations were performed using SPPS
11.0.
Results
Development of a mouse TAT-ELISA
Generation of rabbit antibodies against mouse thrombin and rat 
antithrombin
Rabbits were immunized with mouse thrombin or with
rat antithrombin (AT). Before immunization neither of
the rabbits exhibited immunoreactivity towards (xeno-
genic) thrombin and AT (data not shown). Twenty-five
days after immunization the rabbits exhibited a response
against the immunizing protein, which reached maximal
levels 50 days after immunization. Serum immune titers
of each rabbit were determined by ELISA. Serum samples
of rabbits immunized with thrombin could be diluted
more than 25,000-fold before the reactivity with
thrombin reached background level (data not shown).
Serum samples of rabbits immunized with AT could even
be diluted 100,000-fold before reaching background sig-
nal (data not shown). Since antibodies from two rabbits
recognized thrombin or antithrombin with equal immu-
noreactivity, sera from each pair of animals were pooled
and used for further experiments (data not shown).
Western blot analysis showed that serum from rabbits
immunized with thrombin, reacted only with thrombin
(lane T) and not with antithrombin (lane AT) (Figure 1A).
In the lane loaded with in vitro TAT complexes, two bands
were observed of respectively 39 kD and 94 kD. The 39 kD
band represents thrombin, whereas the 94 kD corre-
sponds to the reported molecular weight of TAT com-
plexes [7]. Besides prothrombin (72 kD), TAT-complexes
were detected in plasma samples from LPS-treated mice
(Figure 1A, lanes 1 through 4), indicating proper recogni-
tion of TAT-complexes in mouse plasma by the rabbit α-
thrombin antibodies.
With serum obtained from rabbits immunized with
mouse AT, opposite results were obtained. No band was
detectable in the lane loaded with thrombin while a 58
kD band was detectable in the lane loaded with AT (Figure
1B). The two upper bands, also detected in the plasma
samples, are multimeric complexes of AT. Again, two
bands were detected in the TAT-lane: one band of 58 kD,
representing uncomplexed AT, and a 94 kD TAT complex
band. Western-blot analysis of plasmas obtained from
LPS-treated mice showed the presence of TAT-complexes
Antithrombin (lane AT), thrombin (lane T) and in vitro TAT  complexes (lane TAT) were separated on a 7.5% acrylamide  gel and transferred to a nitrocellulose filter Figure 1
Antithrombin (lane AT), thrombin (lane T) and in vitro TAT 
complexes (lane TAT) were separated on a 7.5% acrylamide 
gel and transferred to a nitrocellulose filter. Plasma samples 
of control mice (lane 1) or mice treated with 50 µg/ml LPS 
for 2 (lane 2), 6 (lane 3) and 24 hours (lane 4) were sepa-
rated also. The filters were incubated with 1000-fold diluted 
serum from a rabbit immunized with thrombin (A), or serum 
from a rabbit immunized with AT (B).
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recognized by the rabbit α-AT antibodies (Figure 1B, lanes
1 through 4).
Development of TAT-complex sandwich ELISA
To discriminate and select between capture and conjugat-
ing antibody, protein-A purified rabbit α-thrombin anti-
bodies and rabbit α-AT antibodies were conjugated to
digoxigenin (DIG). In brief, using 96-wells plates coated
with thrombin or AT it was confirmed that DIG was suc-
cessfully conjugated to both antibodies (data not shown).
Subsequently, 96-wells plates were coated with either rab-
bit α-thrombin antibodies or rabbit α-AT antibodies in a
concentration of 1 µg/ml. Thereafter, the plates were incu-
bated with two-fold serial dilutions of in vitro TAT-com-
plexes. Plates coated with rabbit α-AT antibodies were
subsequently incubated with serial dilutions of DIG-con-
jugated rabbit α-thrombin antibodies, whereas plates
coated with rabbit α-thrombin antibodies were incubated
with serial dilutions of DIG-conjugated rabbit α-AT
antibodies.
The use of rabbit α-thrombin capture antibodies was
superior to rabbit anti-rat antithrombin capture antibod-
ies in combination with DIG-conjugated rabbit α-
thrombin as detection antibodies in the detection of TAT-
complexes, even at low concentration of secondary anti-
body (Figure 2A and 2B). Furthermore, the background
signal was virtually zero in the absence of TAT-complexes
and a 2000-fold dilution of DIG-conjugated rabbit α-AT
antibodies. Detection of TAT-complexes using the combi-
nation of rabbit  -AT antibodies as capture antibody and
DIG-conjugated rabbit α-thrombin antibodies as
detection antibody showed lower specificity compared to
the reverse setup (Figure 2B). Therefore, for further exper-
iments the rabbit α-thrombin antibodies and DIG-conju-
gated rabbit α-AT antibodies were used as capture
antibody and detection antibody, respectively.
To further prove the possibility that positive results were
caused by cross reactivity of rabbit α-thrombin antibodies
with AT or vice versa, plates coated with rabbit α-
thrombin antibodies were incubated with serial dilutions
of thrombin or AT alone and thereafter incubated with
DIG-conjugated rabbit α-AT antibodies. Neither
thrombin nor AT alone were detected in this analysis
(data not shown).
In vitro TAT-complexes were generated in order to be used
as standard. The linearity of standard diluted in buffer was
similar to the linearity upon dilution in mouse plasma or
Selection of capture and conjugating antibody Figure 2
Selection of capture and conjugating antibody. 96-wells plates were coated with either rabbit anti-mouse thrombin antibodies 
(Panel A) or rabbit anti-rat antithrombin antibodies (Panel B) prior to incubation with two-fold serial dilutions of in vitro TAT-
complexes. Plates coated with rabbit α-AT antibodies were subsequently incubated with serial dilutions of DIG-conjugated 
rabbit α-thrombin antibodies, whereas plates coated with rabbit α-thrombin antibodies were incubated with serial dilutions of 
DIG-conjugated rabbit α-AT antibodies.
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pooled human pool plasma (data not shown). While
lower OD's were detected for standard diluted in human
plasma as compared to buffer, the slopes of the linear part
of the curves of standard diluted in human plasma (slope
= 0.45, r2 = 0.996) or buffer (slope = 0.43, r2 = 0.998) were
similar.
Using frozen aliquots of in-vitro TAT-complexes as stand-
ard, the intra- and inter-assay coefficients of variation
(CV) of the ELISA were determined. The intra-assay CV
were assessed by measuring TAT values in three samples
each from different aliquots (n = 5) on one plate. The
mean TAT concentration in the three samples was 5.1,
11.3 and 15.4 ng/ml and the corresponding CV were 7.7,
6.6 and 5.5 %. The three samples with different TAT levels
were also analyzed on five separate ELISA plates and the
inter-assay CV were 7.0, 5.1 and 4.7 %, respectively.
Comparision of three TAT ELISA's in vitro
Detection of TAT-levels in standard prepared from in vitro
TAT-complexes was compared between three ELISA meth-
ods: 1. the mouse specific TAT ELISA as described in Mate-
rials and Methods, 2. the human specific Enzygnost® TAT
micro from Dade Behring, and 3. the human specific TAT
ELISA from ERL. Using the human specific TAT ELISA
Comparison of three TAT ELISA's using in vitro TAT-complexes diluted in buffer (Panel A) or normal mouse pool plasma  (Panel B) Figure 3
Comparison of three TAT ELISA's using in vitro TAT-complexes diluted in buffer (Panel A) or normal mouse pool plasma 
(Panel B). In vitro TAT-complexes were generated according to the method from Boisclair et al. (8). TAT-levels in serial dilu-
tions of standards were measured by the mouse specific TAT ELISA (), the human specific TAT ELISA from Enzyme Research 
Laboratories (), and the human specific Enzygnost® TAT micro from Dade Behring (❍ ).
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TAT-complex levels in mouse plasma after two different  blood drawing techniques, determined with the home made  TAT assay Figure 4
TAT-complex levels in mouse plasma after two different 
blood drawing techniques, determined with the home made 
TAT assay. Plasma samples were obtained by either collec-
tion of venous blood in a syringe filled with 180 µl 3.2 %(w/v) 
citrate (Citrate in Syringe) or by i.v. injection of 3.2% (w/v) 
sodium citrate (body weight (gr) / 13 × 10 µl) into the vena 
cave 20–30 seconds before blood drawing (Citrate in Vein).
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from ERL, a standard curve comparable to the mouse spe-
cific TAT ELISA was obtained by serial dilution of standard
in buffer (Figure 3A). In contrast to the mouse specific
ELISA, both commercial kits failed in detecting in vitro
prepared TAT-complexes after serial dilutions in mouse
plasma (Figure 3B).
Plasma collection procedures
Anticoagulation with sodium citrate
Two different techniques of anticoagulation with sodium
citrate were tested in mice. Collection of venous blood
from the vena cava in a syringe with 0.1 volume sodium
citrate resulted in activation of blood coagulation in four
out of sixteen plasma samples, as indicated by high TAT-
levels > 100 ng/ml, which indicated undesired activation
(Figure 4). Plasma samples obtained by i.v. injection of
sodium citrate (180 µl per mouse) via the vena cava
showed little or no activation of blood coagulation, since
fourteen samples had undetectable TAT-levels of 0 ng/ml
and two with levels of 2 and 13 ng/ml (Figure 4).
Neutralizing heparin in plasma samples
To assess the influence of in vivo injected heparin and its
neutralization with heparinase, APTT and factor VIII activ-
ity were measured. Intravenous injection of 4, 20 and 400
units of heparin prolonged APTT similarly in mouse
plasma by 300 seconds. Neutralizing heparin through
addition of heparinase shortened the APTT significantly
(p < 0.0001) (Figure 5A). The APTT was the same (p = 0.6,
tested by ANOVA) for plasma from mice treated with 4 or
20 units of heparin followed by heparinase neutralization
compared to control plasma. The APTT of plasma pre-
treated with 400 U of heparin also shortened after hepari-
nase addition, though it remained prolonged (169
seconds ± 47) compared to control plasma (29 seconds ±
1). Factor VIII activity was also normalized to normal
levels after treatment with heparinase in plasma from
mice treated with 4 or 20 units of heparin (p = 0.6, tested
by ANOVA) (Figure 5B). The level of factor VIII in plasma
fro mice treated with 400 units of heparin increased after
Neutralizing effect of heparinase on different amounts of heparin was tested Figure 5
Neutralizing effect of heparinase on different amounts of heparin was tested. A) APTT returned to normal levels after hepari-
nase addition to plasma samples from mouse treated with 4 and 20 units of heparin per mouse. B) Also, factor VIII activity 
returned to normal levels after heparinase treatment to plasma samples from mouse treated with 4 and 20 units of heparin.
Increased TAT-complex levels in plasma of LPS-treated mice Figure 6
Increased TAT-complex levels in plasma of LPS-treated mice. 
Plasma samples were collected at 0, 0.5, 1.5, 4, 12, and 24 
hours after i.p. injection of 2 mg/kg LPS. Values are means of 
triplicates ± SD. *; p < 0.05, and **; p < 0.0001.
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heparinase addition (51 ± 5%) but not to the level of con-
trol plasma (125 ± 18%).
TAT measurement in vivo: the effects of LPS administration
To study the kinetics of TAT levels in plasma samples of
endotoxin-treated mice and to evaluate the TAT ELISA,
plasma samples were obtained at various time points after
i.p. LPS administration. In plasma of control mice the TAT
concentration was 1.6 ± 0.4 ng/ml (Figure 6). A 10-fold
increase in TAT values up to 20.9 ± 2.0 ng/ml was
observed in plasma samples obtained 4 hours after LPS
administration. After 24 hours the TAT levels were back at
baseline levels. The TAT levels on t = 0.5, t = 1.5 and t = 4
hours differed significantly from control levels (p < 0.05,
unpaired Student' t-test).
It should be noted that the actual variation in peak TAT
levels was very small in this experiment, which is in con-
trast with the observed range in values in the next
experiment that was done at a later stage in different mice
(Figure 7).
For comparison of in vivo formed TAT complexes in
mouse plasma by the three different ELISA methods, the
standards supplied in each commercial assay were diluted
according to the manufactures instructions and used to
calculate TAT-concentrations. Plasma samples were
obtained from control mice and from mice six hours after
i.p. LPS administration (2 m/kg) by drawing venous
blood after i.v. administration of sodium citrate as
described before. In plasma of control mice TAT
concentration was 2.9 ± 2.9 ng/ml, 9.2 ± 7.7 ng/ml, and
1.1 ± 0.20 ng/ml, measured with respectively the Dade
Behring, ERL, and our own ELISA (Figure 7). After 6 hours
of endotoxemia blood coagulation was activated as indi-
cated by a 30-fold increase in TAT-levels as measured with
the mouse specific TAT ELISA (35.7 ± 21.1 ng/ml; p < 0.05
as compared to control plasma) (Figure 7), whereas TAT
levels measured by the ERL and Dade Behring ELISA's
were 2588.5 ± 1234.0 ng/ml and 37.4 ± 32.4 ng/ml,
respectively. Of note, the response detected ex vivo by the
three assays was quite comparable, whereas the in vitro
comparison suggested that at least in plasma our TAT
assay would be superior as compared to the commercial
assays. We have no proper explanation for this discrep-
ancy. Theoretically, a difference in affinity of the assay
antibodies against the mouse-mouse TAT in ex vivo
plasma as compared to the mouse-rat TAT complexes in
vitro may play a role. Alternatively, the commercial assays
could lack specificity for mouse TAT complexes, which
could also explain the considerabble differences in TAT
concentrations that are between 10–100 fold higher in the
ERL assay as compared to our TAT method. We have no
evidence to substantiate either of these explanantions,
other than that a weak correlation, as measured with
Spearman correlation test, between the mouse specific
TAT ELISA and the human specific ELISA from ERL r =
0.600; p = 0.051 suggests that a similar product is being
detected. No correlation was found between TAT-concen-
tration measured with the mouse specific ELISA and the
TAT-complex levels in mouse plasma without or after 6 hours of endotoxin treatment (2 mg/kg) as measured with the mouse  specific TAT ELISA (panel A), the human specific TAT ELISA from Enzyme Research Laboratories (panel B), or the human spe- cific Enzygnost® TAT micro from Dade Behring (panel C) Figure 7
TAT-complex levels in mouse plasma without or after 6 hours of endotoxin treatment (2 mg/kg) as measured with the mouse 
specific TAT ELISA (panel A), the human specific TAT ELISA from Enzyme Research Laboratories (panel B), or the human spe-
cific Enzygnost® TAT micro from Dade Behring (panel C). No correlation was found between TAT-concentration measured 
with our own ELISA and either the human specific TAT ELISA from Enzyme Research Laboratories (slope = 33.27, r2 = 0.360), 
or the human specific Enzygnost® TAT micro from Dade Behring (slope = 0.73, r2 = 0.132).
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Dade Behring ELISA. A correlation was found between the
two commercial human specific ELISAs (r = 0.694; p <
0.05).
Discussion
Studying the relationship between coagulation changes in
blood and at tissue level in mice requires the availability
of tools for the analysis of coagulation activation. In this
study we evaluated several procedures for plasma
preparation and the measurement of coagulation activa-
tion in a mouse model of endotoxemia. First, we
described the development of a specific mouse sandwich
ELISA to measure the level of TAT complexes in mouse
plasma. Second, we compared three different sandwich
ELISAs for measurement of TAT levels in mouse plasma.
Third, we tested different anticoagulation techniques to
prevent ex vivo clotting.
Using the new TAT ELISA we detected changes in mouse
plasma TAT content 4 hours after endotoxin infusion. Pre-
viously, it was demonstrated that endotoxin treatment of
mice resulted in increased TAT complexes [8], TF mRNA
synthesis [9] and enhanced tissue deposition of fibrin
[10]. In human volunteers endotoxin infusion induced
monocyte TF mRNA expression and plasma F1+2 and TAT
levels [11]. Therefore, we expected an increase of TAT lev-
els in plasma of mice treated with endotoxin. Indeed,
basal TAT levels of 1.6 ± 0.4 ng/ml were increased in mice
treated with endotoxin with maximal levels of 20.1 ± 9.9
ng/ml after 4 hours.
In addition to the mouse specific TAT ELISA, the two com-
mercially available human TAT ELISAs, Enzygnost® TAT
micro from Dade Behring and the TAT ELISA from
Enzyme Research Laboratories also detected increases in
TAT levels after endotoxin treatment in mice. However,
significant differences between the three assays were
observed. The levels of TAT complexes as measured with
the ERL assay were about 70 fold higher as compared to
the two other assays. Furthermore, the Dade Behring assay
could not detect in vitro prepared TAT complexes diluted
in either buffer or plasma and in vivo TAT levels did not
correlate to the levels measured with the mouse specific
ELISA. Since plasma levels of TAT complexes measured by
the ERL ELISA correlated to levels measured with the
mouse specific ELISA, we speculate that this assay has
probably a slightly better specificity for mouse TAT com-
plexes than the Dade Behring assay. In addition, the ERL
ELISA could measure in vitro prepared TAT complexes
diluted in buffer. Still, the substantial variation in meas-
ured TAT concentrations suggests that the ERL assay,
developed for use in human plasma, is not sufficiently
specific for mouse TAT complexes. In additioon to these
practical considerations and limitations, the considerable
costs of the commercial human assays makes by compar-
ison our novel assay to a cheaper and probably reliable
alternative for the analysis of mouse TAT complexes in
plasma samples.
For  ex vivo anticoagulation sodium citrate is the most
commonly used reagent added to human plasma. Since
we experienced that anticoagulation with sodium citrate
or EDTA in the syringe did not always effectively prevent
ex vivo clotting of mouse blood, an alternative method of
anticoagulation was sought. This led to a novel method to
anticoagulate the blood samples in which sodium citrate
was injected intravenously into the vena cava 20–30 sec-
onds before blood collection by exsanguination. In our
experiments, TAT levels were not increased in any of the
plasma samples obtained using the i.v. injection of
sodium citrate method, in contrast to the standard
method in which sodium citrate was added to blood in
the syringe. Therefore, we conclude that anticoagulation
of mouse blood by i.v. injection of sodium citrate into the
circulation results in more reliable TAT data and in plasma
more suitable for further analysis of coagulation and
related factors.
For immunohistochemical analyses of tissues patholo-
gists may prefer the infusion of heparin prior to sacrificing
the animal. To determine whether this anticoagulant
effect could be eliminated to allow other assays including
plasma based clotting tests, we tested the neutralizing
activity of heparinase in mouse plasma. In accordance
with results in human plasma we confirmed that up to 20
units of heparin per mouse, prolonging the APTT to more
than 300 seconds, could be adequately neutralized with
heparinase as indicated by normalized FVIII activity and
APTT levels [6].
Conclusion
In conclusion, the home made ELISA for mouse TAT com-
plexes detects thrombin generation after endotoxin chal-
lenge in mice. Applied to blood samples obtained after
systemic citrate infusion, this methodology may improve
the quality of studies aimed at elucidating the pathophys-
iology of coagulation activation in mice.
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